CRISPR Therapeutics’ (CRSP) “Neutral” Rating Reiterated at Cantor Fitzgerald

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “neutral” rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports.

CRSP has been the subject of several other reports. Robert W. Baird increased their price target on CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a report on Thursday. Barclays boosted their price target on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Citigroup increased their target price on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Needham & Company LLC dropped their price objective on CRISPR Therapeutics from $90.00 to $88.00 and set a “buy” rating on the stock in a report on Thursday. Finally, TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $73.67.

CRISPR Therapeutics Stock Performance

CRSP stock traded down $0.53 during mid-day trading on Thursday, reaching $52.76. The company had a trading volume of 610,924 shares, compared to its average volume of 1,747,704. CRISPR Therapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of -26.72 and a beta of 1.80. The firm has a fifty day simple moving average of $65.81 and a 200 day simple moving average of $64.64.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. The business’s revenue was down 99.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.67) EPS. As a group, analysts predict that CRISPR Therapeutics will post -6.24 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the transaction, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the transaction, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at $15,057,615.72. The disclosure for this sale can be found here. Insiders have sold 83,992 shares of company stock worth $6,132,335 in the last ninety days. 4.10% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently bought and sold shares of CRSP. Raymond James Financial Services Advisors Inc. lifted its position in CRISPR Therapeutics by 21.7% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 33,378 shares of the company’s stock valued at $1,515,000 after purchasing an additional 5,948 shares during the last quarter. Stratos Wealth Partners LTD. increased its stake in CRISPR Therapeutics by 28.2% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 5,580 shares of the company’s stock valued at $253,000 after buying an additional 1,226 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in CRISPR Therapeutics by 11.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,527 shares of the company’s stock valued at $841,000 after buying an additional 1,879 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in CRISPR Therapeutics by 10.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 184,854 shares of the company’s stock valued at $8,391,000 after buying an additional 17,258 shares during the period. Finally, TD Asset Management Inc increased its stake in CRISPR Therapeutics by 12.9% during the 3rd quarter. TD Asset Management Inc now owns 240,462 shares of the company’s stock valued at $10,915,000 after buying an additional 27,387 shares during the period. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.